

Utilization patterns of Direct Oral Anticoagulants in Medicare Beneficiaries with Cancer

and Non-valvular Atrial Fibrillation

Shirin Ardeshirrouhanifard, Pharm D, MPH, PhD¹, Huijun An, MS¹, Ravi K. Goyal, MS², Mukaila A. Raji, MD, MS³, Jodi B. Segal, MD, MPH¹, G. Caleb Alexander, MD, MS¹, Hemalkumar B. Mehta, PhD¹

¹ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

² College of Pharmacy, University of Houston, Houston, Texas ³ Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas

BACKGROUND

- Individuals with cancer are at increased risk of atrial fibrillation (AF) and associated stroke and bleeding [1-2].
- Major clinical trials have shown non-inferiority or superiority of direct oral anticoagulants (DOACs) over warfarin to reduce the risk of stroke or thromboembolism while having decreased risk of bleeding [3].
- There are no specific recommendations for anticoagulation for individuals with non-valvular atrial fibrillation (NVAF) and cancer.
- National patterns of oral anticoagulant use and factors associated with its use are lacking in individuals with cancer and NVAF.

OBJECTIVES

To characterize use and patient characteristics associated with warfarin and DOACs among individuals with cancer and incident NVAF.

METHODS

- <u>Data</u>: SEER-Medicare linked database from 2010 to 2016.
- **Study Population:** Individuals who were diagnosed with primary cancer (breast, bladder, colorectal, esophagus, lung, ovary, kidney, pancreas, prostate, stomach, and uterus) and newly diagnosed with NVAF after cancer diagnosis.
- **Exposure:** Warfarin or DOACs (dabigatran, rivaroxaban, apixaban and edoxaban)
- Statistical methods: We assessed:
- 1) time to initiation of any oral anticoagulant using Cox proportional hazards regression model.
- 2) use of any DOACs or warfarin using logistic regression model.
- We included sociodemographic factors, cancer characteristics, comorbidities, comedications, CHA₂DS₂-VASc score, and HAS-BLED score in both models.




Figure 1. Trend of use of oral anticoagulants in individuals with cancer and NVAF

Figure 2. Patient Characteristics Associated with Initiation of Direct-Acting Oral Anticoagulants rather than Warfarin among Patients with Non-Valvular Atrial Fibrillation after Cancer Diagnosis

	All patients	DOAC	Odds ratio	
Sociodemographic characteristics	N=8,046	rate,%	(95% CI)	
Age (5 years)			0.96 (0.92, 0.999)	•
Race/ethnicity (ref: Non-Hispanic White)	7,102 (88.3)	56.0		
Black	475 (5.9)	48.6	0.80 (0.64, 0.998)	
Hispanic	108 (1.3)	45.4	0.98 (0.63, 1.52)	
Other	361 (4.5)	58.7	1.10 (0.86, 1.40)	
Income (ref: Q1)	1,745 (21.7)	52.3		
Q2	1,942 (24.1)	49.6	0.79 (0.69, 0.92)	
Q3	2,009 (25.0)	55.5	1.02 (0.88, 1.19)	
Q4	2,135 (26.5)	63.1	1.43 (1.23, 1.67)	
Medicaid eligibility	1,707 (21.2)	50.0	0.98 (0.86, 1.12)	
Census region (ref: West)	3,472 (43.2)	56.5		
South	3,290 (40.9)	53.2	0.86 (0.77, 0.96)	
Northeast	509 (6.3)	65.0	1.74 (1.39, 2.16)	
Midwest	703 (8.7)	54.3	0.94 (0.78, 1.13)	
Others	72 (0.9)	61.1	0.71 (0.38, 1.30)	
				0.25 0.50 1.0 2.0 5.0 15.0
			LECTRON TO THE	

	All patients	DOAC	Odds ratio	
Clinical characteristics	N=8,046	rate, %	(95% CI)	
CHA2DS2-VASc Score (ref: 1)	130 (1.6)	63.9		
2	707 (8.8)	63.5	0.81 (0.52, 1.26)	
3	1,415 (17.6)	62.1	0.77 (0.50, 1.19)	-
4	1,820 (22.6)	58.2	0.69 (0.44, 1.07)	-
5	1,582 (19.7)	54.7	0.63 (0.40, 0.99)	-
>=6	2,392 (29.7)	47.3	0.53 (0.33, 0.84)	
HAS-Bled score (ref: >= 6)	641 (8.0)	48.4		
5	991 (12.3)	52.0	1.11 (0.89, 1.39)	
4	1,741 (21.6)	51.5	0.95 (0.76, 1.17)	
3	2,591 (32.2)	56.4	1.07 (0.86, 1.32)	
2	1,767 (22.0)	62.9	1.20 (0.94, 1.53)	
1	315 (3.9)	55.6	0.83 (0.58, 1.19)	-
Anemia	3,135 (39.0)	52.4	0.99 (0.89, 1.11)	-
Asthma	942 (11.7)	54.5	1.01 (0.86, 1.19)	
COPD	2,621 (33.8)	52.1	0.94 (0.84, 1.05)	-
Coronary revascularization	121 (1.5)	53.7	0.54 (0.36, 0.80)	
Dementia	282 (3.5)	51.4	0.91 (0.69, 1.20)	
Gout	661 (8.2)	53.1	0.84 (0.70, 1.003)	-
Hyperlipidemia	5,953 (74.0)	56.1	1.08 (0.95, 1.23)	-
Inflammatory arthritis	267 (3.3)	50.9	0.95 (0.72, 1.24)	
Other Ischemic heart disease	3,161 (39.3)	53.1	1.01 (0.90, 1.13)	-
Other cerebrovascular disease	272 (3.4)	72.4	1.17 (0.86, 1.60)	-
Peptic ulcer disease	224 (2.8)	45.5	0.88 (0.65, 1.19)	-

Note: The results in the figure are from a multivariable logistic regression model that included sociodemographic, clinical, and cancer related characteristics as well as co-medications.

RESULTS

- Of 27,702 individuals, 8,046 (29.0%) initiated oral anticoagulants, of whom 4,469 (55.5%) initiated DOACs and 3,577 (44.5%) initiated warfarin.
- Overall, the use of oral anticoagulants increased from 27.3% in 2010 to 31.5% in 2016 (*P*<0.0001 for trend).
- Oral anticoagulant initiation was less likely among older individuals (HR 0.92, 95% CI 0.91-0.94 for each 5-year increase), and non-Hispanic black race (HR 0.81, CI 0.73-0.89 compared to non-Hispanic White race).
- Anticoagulant use was more likely among those with CHA2DS2-VASc score of 4 or more (e.g., HR 1.55, CI 1.27-1.90 for CHA₂DS₂-VASc score ≥6 vs. 1) or those with lower HAS-BLED scores.
- Compared to CHA₂DS₂-VASc score of 1, individuals with score of 5 (OR 0.60, 95%CI 0.39-0.94) or score of 6 or more (OR 0.63, CI 0.40-0.99) had lower likelihood of using DOACs than warfarin (Figure 2).

CONCLUSION

- Nearly seven out of ten individuals with cancer and NVAF did not receive oral anticoagulation in 2016 which may represent potential underuse of oral anticoagulants in this vulnerable population.
- Increasing DOAC use from 2010 to 2016 was offset by decreasing warfarin use.
- DOACs are used less than warfarin among those at higher risk of stroke.

REFERENCES

- 1. Conen D, Wong JA, Sandhu RK, et al. Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. *JAMA cardiology.* 2016;1(4):389-396.
- 2. Kattelus H, Kesäniemi YA, Huikuri H, Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). *PloS one.* 2018;13(10):e0205454.
- 3. Buza V, Rajagopalan B, Curtis Anne B. Cancer Treatment–Induced Arrhythmias. *Circulation: Arrhythmia and Electrophysiology.* 2017;10(8):e005443.